956025-35-7

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 456-22-4 4-Fluorobenzoic acid 
• 109-77-3 malononitrile 

Downstream Products

• 954221-24-0 [(4-fluorophenyl)(methoxy)methylidene]propanedinitrile 
• 338391-69-8 1-tert-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1627744-62-0 C₁₃H₁₅FN₄O 
• 1627744-50-6 C₁₃H₁₃FN₄ 
• 1627744-34-6 C₁₀H₉FN₄O 
• 171742-31-7 C₁₀H₇FN₄ 

Relevant academic research and scientific papers

SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF

The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4- carboxamide derivatives as potential antitumor agents

Adenosine deaminase (ADA) inhibitors have been found to have antitumor activities. Here, thirteen potential adenosine deaminase inhibitors 5-amino-1H-pyrazole-4-carboxamide derivatives were designed, synthesized and screened for antitumor activities. Comp

MODULATION OF PROTEIN TRAFFICKING

Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.

INHIBITION OF ALPHA-SYNUCLEIN TOXICITY

Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease.